Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,322 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Recruiting Phase 1Phase 2 Interventional

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

NCT07594626
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Indomethacin in Chronic Pancreatitis

NCT04207060
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

NCT01013896
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Motivational Interviewing, Cystic Fibrosis Education
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study

NCT04112069
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 15, 2026, 5:32 AM EDT
Completed No phase listed Observational

Examination of the Pancreas in New-onset Diabetes

NCT02001337
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
medical chart review, survey administration, Specimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

NCT00041639
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
5
States / cities
Newport Beach, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

NCT05247905
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
171
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

NCT01951729
View directory record Official record
Conditions
Pre-diabetes
Interventions
Control, Xenin-25 without atropine, GIP without atropine, Placebo with atropine, Xenin-25 with atropine, GIP with atropine, GIP plus Xenin-25 without atropine, GIP plus Xenin-25 with atropine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

NCT07481383
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Non-resectable
Interventions
ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
Combination Product
Lead sponsor
Continuity Biosciences, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-9805, RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Results available

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 15, 2026, 5:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

NCT07026981
View directory record Official record
Conditions
Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
Interventions
[Ga-68]MTP220 PET/CT Scan
Drug
Lead sponsor
Qiubai Li
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 15, 2026, 5:32 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT05411094
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

NCT05998629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels, Standard of Care laboratory procedure for measurement of sweat
Device · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chemoradiation-Induced Nausea and Emesis: Quality of Life

NCT00394602
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer, Cervical Cancer, Vulvar Cancer, Endometrial Cancer, Anal Cancer
Interventions
Interview, Questionnaire
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain

NCT01159119
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUR-1066-A, Zenpep, EUR-1066-B
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT00426127
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Docetaxel, Liposomal Doxorubicin, Enoxaparin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 15, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07454642
View directory record Official record
Conditions
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
AVA6103
Drug
Lead sponsor
Avacta Life Sciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

NCT00533442
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 15, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Videoendoscopic Drainage of Infected Pancreatic Collections

NCT00061269
View directory record Official record
Conditions
Pancreatitis, Acute Necrotizing
Interventions
Videoscopic-Assisted Retroperitoneal Debridement (VARD)
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
5
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 15, 2026, 5:32 AM EDT
Not listed No phase listed Observational

Pancreatic Cancer & Surgical Resection

NCT05170802
View directory record Official record
Conditions
Pancreas Cancer
Interventions
NanoKnife procedure
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 15, 2026, 5:32 AM EDT